Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

USFDA grants Sun Pharma subsidiary approval for generic Strattera capsules ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Strattera ®, atomoxetine hydrochloride capsules.

2 Sep 2010

Children, teens need good health before the start of new school year, says medical director

With the back to school shopping season in full swing, it is also important to arm area children and teens with other tools they need to have a good school year- like medical exams. These are critical to good health and should take place before or shortly after the start of the new school year, and include a routine doctor's exam to confirm that all immunizations are up-to-date, a dental check-up, and a vision exam.

30 Aug 2010

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

30 Aug 2010

23rd ECNP Press conference on impact of circadian rhythms on human brain

All humans are synchronised to the rhythmic light-dark changes that occur on a daily basis. Rhythms in physiological and biochemical processes and behavioural patterns persist in the absence of all external 24-hour signals from the physical environment, with a period that is close to 24 hours

30 Aug 2010

Simple medical exams recommended for school-age children

Many children and teens are enjoying the remaining days of their summer vacation, but are they truly prepared for what lies ahead? With a few simple medical exams, Virginia's school-age children will be armed with the tools they need to enjoy a healthy school year. The exams we are referring to are given in a doctor's and/or dentist's office, and should take place before or shortly after the start of the new school year, and include a routine doctor's exam to confirm that all immunizations are up-to-date, a dental exam and a vision exam.

27 Aug 2010

KemPharm broadens protection for LAT prodrug technology platform for ADHD with second patent

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same", U.S. Patent No. 7,776,917 B2. This patent, combined with KemPharm's recently issued U.S. Patent No. 7,772,222, provides broad protection of the Company's Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

27 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

26 Aug 2010

Worldwide conference to discuss increase in autism, help restore health

The Centers for Disease Control and Prevention (CDC) recently released new estimates that one in every 110 children (1 in 70 boys) is diagnosed with autism. Autism has become more common in our children than cancer, diabetes and AIDS combined. Autism affects children from all socioeconomic and ethnic backgrounds and places a tremendous economic burden on affected families and society at large, costing up to $3.2 million per child for a lifetime of care and over $35 billion in annual societal cost.

26 Aug 2010

Cognitive behavioral therapy improves ADHD symptoms in adults: Study

Adults with attention-deficit/hyperactivity disorder (ADHD) who received medication and individual sessions of cognitive behavioral therapy (CBT) showed greater improvement in symptoms through 12 months compared to patients who did not receive CBT, according to a study in the August 25 issue of JAMA.

25 Aug 2010

Study finds multi-modal hemispheric based program improves participant's educational outcomes

A new ADD/ADHD study found that a multi-modal hemispheric based program significantly improved the participant's educational outcomes. The study, "The Effect of Hemispheric Specific Remediation Strategies on the Academic Performance Outcome of Children With ADD/ADHD," was conducted by a research team including, Gerry Leisman, Robert Melillo, Sharon Thum, Mark Ransom, Michael Orlando, Christopher Tice, and Frederick Carrick. The study appears in the current issue of the International Journal of Adolescent Medicine and Health.

24 Aug 2010

NARSAD announces 2010 Independent Investigator grants for innovative researchers

NARSAD announced its 2010 Independent Investigator grants totaling in excess of $4.1 million, which will support 42 innovative researchers at the leading edge of discovery within neuroscience and psychiatry. Since 1987 NARSAD has awarded more than $261.6 million in 3,832 grants to 3,132 scientists around the world.

24 Aug 2010

NSF issues award to develop techniques for analyzing children's behavior

A team led by the Georgia Institute of Technology has received a $10 million "Expeditions in Computing" award from the National Science Foundation (NSF) to develop novel computing techniques for measuring and analyzing the behavior of children.

20 Aug 2010

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).

20 Aug 2010

Prenatal pesticide exposure increases susceptibility to ADHD in children

Exposure to organophosphate (OP) pesticides before birth can increase susceptibility to attention disorders such as attention deficit/hyperactivity disorder (ADHD), according to new research published in the journal Environmental Health Perspectives (EHP). The new study is part of a growing body of research indicating that exposure to OP pesticides can adversely affect brain development.

19 Aug 2010

Teachers' perceptions of poor behavior leads to potential misdiagnosis of ADHD

Nearly 1 million children in the United States are potentially misdiagnosed with attention deficit hyperactivity disorder simply because they are the youngest - and most immature - in their kindergarten class, according to new research by a Michigan State University economist.

18 Aug 2010

Study links child’s date of birth with ADHD diagnosis rate

Rising rates of attention deficit hyperactivity disorder (ADHD) and large differences in diagnosis rates have led to fears that the condition is often being misdiagnosed. A new study from North Carolina State University demonstrates that these concerns are justified. The researchers found large discrepancies in diagnosis and treatment rates based on small differences in children's dates of birth.

18 Aug 2010

BioMarin commences Phase 3b study of Kuvan's neuropsychiatric effects in phenylketonuria patients

BioMarin Pharmaceutical Inc. announced today that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms in subjects with phenylketonuria (PKU). BioMarin expects to report results in the first half of 2012.

18 Aug 2010

Cortex second-quarter net loss decreases to $0.04 per share

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of approximately $2,454,000, or $0.04 per share, for the quarter ended June 30, 2010, compared with a net loss applicable to common stock of approximately $2,778,000, or $0.06 per share, for the corresponding prior year period.

16 Aug 2010

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same", U.S. Patent No. 7,772,222. This patent protects broad aspects of the Company's core Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

16 Aug 2010

Shire announces divestiture of Daytrana to Noven Pharmaceuticals

Shire plc, the global specialty biopharmaceutical company, announced the divestiture of Daytrana (methylphenidate transdermal system) to Noven Pharmaceuticals, Inc. Daytrana, which is approved and marketed in the US for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents, will continue to be available for patients through Noven.

11 Aug 2010

Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

USFDA grants Sun Pharma subsidiary approval for generic Strattera capsules ANDA

Children, teens need good health before the start of new school year, says medical director

Latest achievements in brain research and treatment for mental disorders

23rd ECNP Press conference on impact of circadian rhythms on human brain

Simple medical exams recommended for school-age children

KemPharm broadens protection for LAT prodrug technology platform for ADHD with second patent

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Worldwide conference to discuss increase in autism, help restore health

Cognitive behavioral therapy improves ADHD symptoms in adults: Study

Study finds multi-modal hemispheric based program improves participant's educational outcomes

NARSAD announces 2010 Independent Investigator grants for innovative researchers

NSF issues award to develop techniques for analyzing children's behavior

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Prenatal pesticide exposure increases susceptibility to ADHD in children

Teachers' perceptions of poor behavior leads to potential misdiagnosis of ADHD

Study links child’s date of birth with ADHD diagnosis rate

BioMarin commences Phase 3b study of Kuvan's neuropsychiatric effects in phenylketonuria patients

Cortex second-quarter net loss decreases to $0.04 per share

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

Shire announces divestiture of Daytrana to Noven Pharmaceuticals

Industry Focus eBook - Pharmaceutical manufacturing (2nd edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Industry Focus eBook - Pharmaceutical manufacturing (2nd edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in